Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of glofitamab versus investigator's choice in relapsed/refractory mantle cell lymphoma
CTR20232572Phase 3Active
- Sponsor
- Roche
- Start
- Oct 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of glofitamab in mantle cell lymphoma (MCL), sponsored by Roche. Started Oct 2023; status: active.
02
Drugs
glofitamab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20232572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232572.